Mayo Clinic | Strategic Alliance Partners

October 20, 2016

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.

July 22, 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).

May 26, 2016

Keith C. Bible, MD, PhD, discusses novel treatments he is excited about, the role of lenvatinib, and what the future may hold for thyroid cancer treatment.

April 04, 2016

S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.

March 28, 2016

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.

February 09, 2016

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.

December 22, 2015

S. Vincent Rajkumar, MD, discusses a trial of bortezomib, lenalidomide, and dexamethasone versus lenalidomide plus dexamethasone in patients with previously untreated multiple myeloma.

November 11, 2015

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

October 12, 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

September 27, 2015

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.

September 21, 2015

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

September 01, 2015

Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.

August 25, 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).

August 24, 2015

Grzegorz S. Nowakowski, MD, responds to questions raised regarding the use of immunohistochemistry in his phase II study, as well as future plans for the investigation of R2-CHOP in non-GCB DLBCL.

August 14, 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.

July 23, 2015

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

June 23, 2015

Lead author Asher A. Chanan-Khan, MD, discusses the HELIOS trial, in which adding ibrutinib to bendamustine and rituximab lowered the risk of disease progression by 80% in patients with CLL.

June 23, 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

June 11, 2015

Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.

May 19, 2015

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.